DBV Technologies (DBVT) Capital Expenditures (2020 - 2026)
DBV Technologies (DBVT) posted quarterly Capital Expenditures of $400000.0 for Q2 2026, little changed on a QoQ basis from $400000.0 in Q1 2026.
DBV Technologies (DBVT) Capital Expenditures (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported Capital Expenditures for 7 consecutive years, with $400000.0 the latest figure, recorded in Q2 2026.
- Quarterly Capital Expenditures changed N/A year-over-year to $400000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.3 million (up 391.51% YoY) and the FY2025 annual result came in at $532000.0, down 77.25% from the prior year.
- Capital Expenditures was little changed at $400000.0 in Q2 2026 per DBVT's latest filing, from $400000.0 in the prior quarter.
- Over the last five years, Capital Expenditures for DBVT reached as high as $1.3 million in Q1 2024 and fell as low as -$125000.0 in Q4 2024.
- A 5-year average of $318812.5 and a median of $295000.0 in 2022 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures jumped 2969.23% — and 2024, when it sank 135.51%.
- Year by year, Capital Expenditures stood at $12000.0 in 2022, then soared by 2833.33% to $352000.0 in 2023, then plunged by 135.51% to -$125000.0 in 2024, then jumped by 398.4% to $373000.0 in 2025, then rose by 7.24% to $400000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $400000.0, $400000.0, and $373000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | 400,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 400,000.00 |
| Jun 30, 2026 | 400,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Mar 31, 2026 | 400,000.00 |
| Dec 31, 2025 | 373,000.00 |
| Dec 31, 2025 | 373,000.00 |
| Sep 30, 2025 | 159,000.00 |
| Sep 30, 2025 | 159,000.00 |
| Dec 31, 2024 | -125,000.00 |
| Dec 31, 2024 | -125,000.00 |
| Sep 30, 2024 | 396,000.00 |
| Sep 30, 2024 | 396,000.00 |
| Jun 30, 2024 | 732,000.00 |
| Jun 30, 2024 | 732,000.00 |
| Mar 31, 2024 | 1.34 Mn |
| Mar 31, 2024 | 1.34 Mn |
| Dec 31, 2023 | 352,000.00 |
| Dec 31, 2023 | 352,000.00 |
| Sep 30, 2023 | 50,000.00 |
| Sep 30, 2023 | 50,000.00 |